Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluate the Immunogenicity of a Novel Glucagon Formulation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01959334
First received: October 5, 2013
Last updated: April 26, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2015
  Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 7, 2015